In a recent study published in The Journal of Clinical Endocrinology & Metabolism , researchers developed therapeutic recommendations for utilizing vitamin D [cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2)] to reduce the risk of illness in individuals who do not have documented grounds for vitamin D medication or 25-hydroxyvitamin D [25(OH)D] testing. Studies have linked serum 25-hydroxyvitamin D levels to various ailments, including metabolic, musculoskeletal, neoplastic, cardiovascular, viral, and autoimmune diseases. Although no causative relationship has been proven between blood 25-hydroxyvitamin D levels and numerous illnesses, these links have resulted in widespread vitamin D supplementation and increases in laboratory-based 25-hydroxyvitamin D testing in general populations.
The risk-benefit ratio of the rise in D vitamin usage is unclear, and the ideal vitamin D consumption and significance of 25-hydroxyvitamin D testing to prevent disease are unknown. In the present study, researchers developed guidelines for vitamin D supplementation to prevent disease. An inter-disciplinary panel, including several clinical specialists, identified 14 clinically crucial concerns about vitamin D supplementation and testing to reduce illness risk.
The panel emphasized randomized and placebo-controlled studies in the general public and specific situations (pregnancy and prediabetes) to assess the impact of empirical vitamin D treatment across the life cycle. The panel det.